CUIMC Focal Therapy Registry for Prostate Cancer

This study is a registry collecting information from men with prostate cancer who are undergoing focal therapy, which is a treatment that targets only the cancerous part of the prostate. The treatments being studied are irreversible electroporation (IRE) or high-intensity focused ultrasound (HIFU). The goal is to understand how well these treatments work over time, including how long patients live without their cancer returning (failure-free survival), measured at 10 years. You may be able to join if you are a man between 40 and 85 years old with prostate cancer that is confined to the organ, and you are receiving IRE or HIFU at Columbia University Irving Medical Center. This is an observational study, meaning no new treatment will be given; instead, information will be collected about your existing treatment.

Study design: This is an observational study planning to enroll 1000 participants. It is not randomized, and no specific phase is mentioned.
What's involved: Not specified in the trial record.
Compensation: Not stated in the trial record.
Follow-up: The primary endpoint, failure-free survival, will be measured at 10 years.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

CUIMC Focal Therapy Registry

Recruiting

Not specifiedAges 40–85Observational

Columbia University

~1,000 participants

Updated 2026-06-03 on ClinicalTrials.gov

What's tested:Focal therapy

At a glance

Recruiting sites

1 of 1 listed site is recruiting right now

RecruitingSuspended, closed, or not yet open

What they're measuring

Failure free survival

Measured over 10 years

Conditions

Prostate Cancer

Where it's being run

1 sites across 1 states

New York1

Who to contact

Izak Faiena

[email protected]

212-305-0114

Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime

Eligibility criteria

Inclusion

Organ-confined prostate adenocarcinoma diagnosed by MRI/ultrasound fusion biopsy within a multiparametric MRI derived region of interest

Clinical stage T2cN0M0 (radiological T3a is permitted)

Multi-parametric MRI at New York-Presbyterian hospital (NYPH) within the past 6 months demonstrating region of interest suspicion level 2 by the Prostate Imaging Reporting and Data System version 2.0 scoring criteria

Transrectal or transperineal ultrasound-guided biopsy with 10 template biopsy cores and 2 MRI-ultrasound fusion targeted biopsy cores from the above MRI-derived region of interest demonstrating:

Age 40 to 85 years of age

Subjects choose to undergo focal therapy and decline alternative treatment (such as active surveillance, radical prostatectomy, radiation therapy, cryosurgery or hormone therapy)

Signed informed consent

Exclusion

Any Gleason score 4+4 outside an MRI-identified region of interest

Prostatic calcifications which in the opinion of the investigator would impede delivery of the energy to tumor in patients choosing HIFU

Any medical condition that would compromise the subject's ability to safely participate in the study

American Society of Anesthesiologists (ASA) criteria of IV or higher

Active urinary tract infection

Rectal fissure, fibrosis, stenosis, or other anatomic abnormality precluding insertion of transrectal device

Active, uncontrolled inflammatory bowel disease

Urinary tract or rectal fistula

Previous urethral sling, artificial urinary sphincter, or penile prosthesis surgery

Any contraindication to MRI (such as contrast allergy, sever claustrophobia, MRI-incompatible prosthesis)

What this trial measures

Failure free survival10 years

Trialytics